Gene-directed enzyme prodrug therapy: a review of enzyme/prodrug combinations

Bibliography

• JARMAN M: The development of anticancer drugs. Chem-isfry ill Britain (1989) 25:51–54.
   Google Scholar
• ZHANG WW, FUJIWARA T, GRIMM EA, ROTH JA: Advances in cancer gene therapy. Adv. Pharmacol. (1995) 12:289–341.
   Google Scholar
• BRIDGEWATER G, SPRINGER CJ, KNOX R et al: Expres-sion of the bact erialnitroreductas e enzyme in mammal-ian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer (1995) 31A:2362–2370.
   PubMed Web of Science ®Google Scholar
• MARAIS R, SPOONER RA, LIGHT Y, MARTIN J, SPRINGER CJ: Gene-directed enzyme prodrug therapy with a mus-tard prodrug/carboxypeptidase G2 combination. Can-cer Res. (1996) 56:4735–4742.
   PubMed Web of Science ®Google Scholar
• HUBER BE, RICHARDS CA, AUSTIN EA: An enzyme/pro-drug gene therapy approach for the treatment of me-tastatic colorectal cancer. Adv. Drug Del. Rev. (1995) 17:279–292.
   Web of Science ®Google Scholar
• MARTIN LA, LEMOINENR: Direct cell killing by suicide genes. Cancer Metastasis Rev. (1996) 15:301–316.
   PubMed Web of Science ®Google Scholar
• CARUSO M: Gene therapy against cancer and HIV infec-tion using the gene emoding herpes simplex virus thymidine kinase. Mol Med. Today (1996) 2:212–217.
   PubMedGoogle Scholar
• VILE R, RUSSELL SJ: Gene transfer technologies for the gene therapy of cancer. Gene Ther. (1994) 1:88–98.
   PubMed Web of Science ®Google Scholar
• MILLER N, VILE R: Targeted vectors for gene therapy. FASEB J. (1995) 9:190–199.
   PubMed Web of Science ®Google Scholar
• VILE R: Tumour-specific gene expression. Semin. Cancer Biol. (1994) 5:429–436.
   PubMed Web of Science ®Google Scholar
• DEONARAIN MP, EPENETOS AA: Targeting enzymes for cancer therapy: old enzymes in new roles. Br. J. Cancer (1994) 70:786–794.
   PubMed Web of Science ®Google Scholar
• VILE R, RUSSELL SJ: Retroviruses as vectors. Br. Med. Bull. (1995) 51:12–30.
   PubMed Web of Science ®Google Scholar
• BEHR JP: Synthetic gene-transfer vectors. Account Chem. Res. (1993) 26:274–279.
   Web of Science ®Google Scholar
• LEDLEY F: Non viral gene therapy: the promise of genes as pharmaceutical products. Human Gene 7her. (1995) 6:1129–1144.
   PubMed Web of Science ®Google Scholar
• BEHR JP: Gene transfer with synthetic cationic am-phiphiles: prospects for gene therapy. Bioconj Chem. (1994) 5:382–389.
   PubMed Web of Science ®Google Scholar
• WADHAWA MS, COLLARD WT, ADAMI RC at al: Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconj. Chem. (1997) 8:81–88.
   PubMed Web of Science ®Google Scholar
• KURIYAMA S, NAKATANI T, MASUI K et al: Evaluation ofprodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene. Anti-cancer Res. (1996) 16:2623–2628.
   PubMed Web of Science ®Google Scholar
• VILE R, MILLER N, CHERNAYOVSKY Y, HART I: A compari-son of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or 11-2 genes. Gene Ther. (1994) 1:307–316.
   PubMed Web of Science ®Google Scholar
• TANAKA T, KANAI F, OKABA S et al.: Adenovirus-medi-ated prodrug gene therapy for carcinoembryonic anti-gen-producing human gastric carcinoma cells in vitro. Cancer Res. (1996) 56:1341–1345.
   PubMed Web of Science ®Google Scholar
• KO SC, CHEONG J, KAO C et al.: Osteocalcin promoter-based toxic gene therapy for the treatment of osteosar-coma in experimental models. Cancer Res. (1996) 56:4614–4619.
   PubMed Web of Science ®Google Scholar
• GOLUMBEK PT, HAMZEH FM, JAFFEE EM et al Herpessimplex-1 virus thymidine kinase gene is unable to completely eliminate live, non-immunogenic tumour cell vaccines. J. Immunother. (1992) 12:224–230.
   PubMed Web of Science ®Google Scholar
• HUBER BA, RICHARDS CA, KRENIT SKY TA: Retroviral-me-diated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci USA (1991) 88:8039–8043.
   PubMed Web of Science ®Google Scholar
• AVERETT DR, KOZALKA A, FYFE JA et al.: 6-Methoxy-ptirine arabinoside as a selective and potent inhibitor of varicella-zoster virus. Antimicrob. Agents Chemother. (1991) 35:851–857.
   PubMed Web of Science ®Google Scholar
• DE MIRANDA P, BURNETTE TC, BIRON KK et al.: Anabolic pathway of 6-methoxypurine arabinoside in cells in-fected with Varicella zoster virus. Antimicrob. Ants Chem other. (1991) 35:2121–2124.
   PubMed Web of Science ®Google Scholar
• DYNAN WS, TJIAN R: Control of eukaryotic messenger RNA synthesis by sequence-specific DNA-binding pro-teins. Nature (1985) 316:774–778.
   PubMed Web of Science ®Google Scholar
• ELION GB: The chemotherapeutic exploitation of virus-specified enzymes. Adv. Enzymes Reg. (1980) 18:53–66.
   PubMedGoogle Scholar
• ALLAUDEEN HS, DESCAMPS J, SEHGAL RK, FOX JJ: Selec-tive inhibition of DNA replication in herpes simplex virus infected cells by 1- (2'-deoxy-2'-fluoro-I3-D-arabinofuranosy0-5-iodocytosine. J. Biol. Chem. (1982) 257:11879–11882.
   PubMedGoogle Scholar
• BI WL, PARYSEK LM, WARNICK R, STAMBROOK PJ: In vitro evidence that metabolic co-operation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Human Gene Ther. (1993) 4:725–731.
   PubMed Web of Science ®Google Scholar
• WALLACE H, CLARKE AR, HARRISON DJ, HOOPER ML, BISHOP JO: Gancyclovir-induced ablation of non-prolif-erating thyrocytes expressing herpes virus thymidine kinase occurs by p53-independent apoptosis. Oncogene (1996) 13:55–61.
   PubMed Web of Science ®Google Scholar
• BLACK ME, NEWCOMB TG, WILSON HM, LOEB LA: Crea-tion of drug-specific herpes simplex virus type-1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. USA (1996) 93:3525–3529.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. (1986) 46:5276–5281.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL WELLS JM: Curability of tumors bearingherpes virus thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. (1990) 82:297–300.
   PubMed Web of Science ®Google Scholar
• MOOLTEN FL, VONDERHAAR BK, MROZ PJ: Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to gancyclovir therapy. Hu-man Gene Ther. (1996) 7:1197–1204.
   PubMed Web of Science ®Google Scholar
• BORELLI E, HEYMAN R, HSI M, EVANS RM: Targeting of an inducible toxic phenotype in animal cell. Proc. Natl. Acad. Sci. USA (1988) 85:7572–7576.
   PubMed Web of Science ®Google Scholar
• HOGANSON DK, BATRA RK, OLSEN JC, BOUCHER RC: Comparison of the effect of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. (1996) 56:1315–1323.
   PubMed Web of Science ®Google Scholar
• GARVER RI, Jr., GOLDSMITH KT, RODU B, HU PC, CURIEL DT: Strategy for achieving selective killing of carcino-mas. Gene Ther. (1994) 1:46–50.
   PubMed Web of Science ®Google Scholar
• VILE RG, HART IR: In vitro and in vivo targeting of gene expressionto melanoma cells. Cancer Res. (1993) 53:962–967.
   PubMed Web of Science ®Google Scholar
• VILE RG, HART IR: Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas fol-lowing direct intratumoral injection of DNA. Cancer Res. (1993) 53:3860–3864.
   PubMed Web of Science ®Google Scholar
• CULVER KW: The role of herpes simplex thymidine kinase gene transfer in the drug treatment of brain tumors. CNS Drugs (1996) 6:1–11.
   Web of Science ®Google Scholar
• CARUSO M, PANIS Y, GAGANDEEP S et aL: Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. USA (1993) 90:7024–7028.
   PubMed Web of Science ®Google Scholar
• WILLS NK, HUANG WM, HARRIS MP et al.: Gene-therapy for hepatocellular carcinoma; chemosensitivity con-ferred by adenovirus mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. (1995) 2:191–197.
   PubMed Web of Science ®Google Scholar
• KANEKO S, HALLENBECK P, KOTANI T et aL: Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. (1995) 55:5283–5287.
   PubMed Web of Science ®Google Scholar
• IDO A, NAKATA K, KATO Y et al.: Gene therapy for hepatoma cells using a retrovirus vector carrying her-pes simplex virus thymidine kinase under the control of human a-fetoprotein gene promoter. Cancer Res. (1995) 55:3105–3109.
   PubMed Web of Science ®Google Scholar
• O'MALLEY, Jr., BW, CHEN SH, SCHWARTZ MR, WOO SLC: Adenovirus-mediated gene therapy for human head and neck squamous cell cancer in a nude mouse model. Cancer Res. (1995) 55 :1080–1085.
   PubMed Web of Science ®Google Scholar
• TONG XW, BLOCK A, CHEN SH etaL: In vivogene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and gancyclovir administra-tion. GynecoL Oncol (1996) 61:175–179.
   PubMed Web of Science ®Google Scholar
• TONG XW, BLOCK A, CHEN SH, WOO SLC, KIEBACK DG: Ade novirus-mediate d thymidine kinase gene transduc-tion in human epithelial ovarian cancer cell lines fol-lowed by exposure to gancyclovir. Anticancer Res. (1996) 16:1611–1618.
   PubMed Web of Science ®Google Scholar
• ROSENFELD ME, WANG M, SIEGAL GP et al. Adenoviral- mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged stir- viva! in SCID mouse model of human ovarian carci-noma. J. Mol. Med. (1996) 74:455–462.
   PubMed Web of Science ®Google Scholar
• MANOME Y, ABE M, HAGEN MF, FINE HA, KUFE DW: Enhancer sequences of the DF3 gene regulate expres-sion of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer. Cancer Res. (1994) 54:5408–5413.
   PubMed Web of Science ®Google Scholar
• YEE D, MCGUIRE SE, BRUNNER N eta].: Adenovirus-me-diated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Human Gene Then (1996) 7:1251–1257.
   Google Scholar
• OSAKI T, TANIO Y, TACHIBANA I et aL: Gene therapy forcarcinoembryonic antigen-producing cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. (1994) 54:5258–5261.
   PubMed Web of Science ®Google Scholar
• EASTHAM JA, CHEN SH, SEHGAL I et al: Prostate cancergene therapy: herpes simplex virus thymidine kinase gene transduction followed by gancyclovir in mouse and human prostate cancer models. Human Gene Ther. (1996) 7:515–523.
   PubMed Web of Science ®Google Scholar
• Clinical protocol list. Cancer Gene Ther. (1995) 2:225–234.
   Google Scholar
• TJUVAJEV JG, FINN R, WATANABE K eta].: Non-invasiveimaging of herp es simplex virus thymidine kinase gene transfer and expression: a potential method for moni-toring clinical gene therapy. Cancer Res. (1996) 56:4087–4095.
   Google Scholar
• MACCOSS M, ROBINS MJ: Anticancer pyrimidines,pyrimidine nucleosides and prodrugs. In: Chemistry of Antitumour Agents. Wilman DEV (Ed.), Blackie & Son Ltd., Chapman & Hall, London, New York (1990):261–298.
   Google Scholar
• MARTIN DS: Plaine and pyrimidine biochemistry andsome relevant clinical and preclinical cancer chemo-therapy research. In: Metabolism and Action ofAnti-cancer Drugs. Powis G, Prough RA (Eds.), Taylor & Francis, London, New York, Philadelphia (1987):91–140.
   Google Scholar
• MULLEN CA, KILSTRUP M, BLAESE RM: Transfer of thebacterial gene for cytosine deaminase to a mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative sele ction system. Proc. Natl. Acad. Sci USA (1992) 89:33–37.
   PubMed Web of Science ®Google Scholar
• HABERKORN U, OBERDORFER F, GEBERT J et al: Moni-toring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine. J. Nucl. Med. (1996) 37:87–94.
   PubMed Web of Science ®Google Scholar
• MULLEN CA, COALE MM, LOVVE R, BLAESE RM: Tumorexpressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. (1994) 54:1503–1506.
   PubMed Web of Science ®Google Scholar
• HUBER BE, AUSTIN EA, GOOD VC et al: In vivo antitumoractivity of 5-fluorocytosine on human colorectal carci-noma cells genetically modified to express cytosine deaminase. Cancer Res. (1993) 53:4619–4626.
   PubMed Web of Science ®Google Scholar
• HUBER BE, AUSTIN EA, RICHARDS CA, DAVIS ST, GOODSS: Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transdiced with the cy-tosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl Acad. Sci USA (1994) 91:8302–8306.
   PubMed Web of Science ®Google Scholar
• HARRIS JD, GUTIERREZ AA, HURST HC, SIKORA K, LEMOINE NR: Gene therapy for cancer using tumor-spe-cific prodrug activation. Gene Ther. (1994) 1:1–6.
   Google Scholar
• OHWADA A, HIRSCHOWITZ EA, CRYSTAL RG: Regional delivery of an adenovirus vector containing the Es-cherichia colicytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metaslatic to liver. Human Gene Ther. (1996) 7:1567–1576.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN TP, GERSTEN NB, ROSS AF, MIECH RP: Ade-nine as substrate for purine nucleoside phosphorylase. Can. J. Biochem. (1971) 49:1050–1054.
   PubMedGoogle Scholar
• SORSCHER EJ, PENG S, BEBOCK Z et al: Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli deo-D gene to generate toxic purines. Gene Ther. (1994) 1:233–238.
   PubMed Web of Science ®Google Scholar
• HUGHES BW, VVELLS AH, BEB OK Z et al: Bystander killing of melanoma cells using the human tyrosinase pro-moter to express the E. coli purine nucleoside phos-phorylase gene. Cancer Res (1995) 55:3339–3345.
   PubMed Web of Science ®Google Scholar
• PATTERSON AV, ZHANG H, MOGHADDAM A et al: In-creased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells& ansfected with thymidine phosphorylase. Br. J. Cancer (1995) 72:669–675.
   PubMed Web of Science ®Google Scholar
• HAPKE DM, STEGMANN APA, MITCHELL BS: Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res (1996) 56: 2343–2347.
   PubMed Web of Science ®Google Scholar
• MANOME Y, WEN PY, DONG Y et al: Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cyto-sine arabinoside in vitro and in vivo. Nature Med. (1996) 2:567–573.
   PubMed Web of Science ®Google Scholar
• MULLIGAN RC, BERG P: Selection for animal cells that express the Escherichia coligene coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. USA (1981) 78:22072–2076.
   Web of Science ®Google Scholar
• TAMIYA T, ONO Y, WEI MX eta].: Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxan-thine or 6-thioguanine. Cancer Gene Ther. (1996) 3:155–162.
   Google Scholar
• TEICHER BA, FREI III, E: Development of alkylating agentresistant human tumor cell lines. Cancer Chemother. Pharmacol. (1988) 21:292–298.
   PubMed Web of Science ®Google Scholar
• FREI E, TEICHER BA, HOLDEN SA: Preclinical studies and clinical correlation of the effect of alkylating drugs. Cancer Res. (1988) 48:6417.
   PubMed Web of Science ®Google Scholar
• SLADEK NE: Oxazaphosphorines. In: Metabolism and Action of Anti-cancer Drugs. Powis G, Prough RA (Eds.), Taylor & Francis, London, New York, Philadelphia (1987): 48–89.
   Google Scholar
• BIELICKI L, VOELCKER G, HOHORST HJ: Activated cyclo-phosphamide: an enzyme-mechanism-based suicide inactivator ofDNA paymerase/3', 5' exonuclease. J. Cancer Res. Clin. Oncol (1984) 107:195–198.
   PubMed Web of Science ®Google Scholar
• CONNORS TA, COX PJ, FARMER PB eta].: Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophos-phamide. Biochem. Pharmacol (1974) 23:115–129.
   Google Scholar
• CHANG TKH, WEBER GF, CRESPI CL, WAXMAN DJ: Differ- ential activation of cyclophosphamide and ifos-phamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. (1993) 53:5629–5637.
   PubMed Web of Science ®Google Scholar
• CHEN L, WAXMAN DJ: Intratumoral activation and en-hanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: develop-ment of a combined chemotherapy/cancer gene ther-apy strategy. Cancer Res. (1995) 55:581–589.
   PubMed Web of Science ®Google Scholar
• HALPERN J, JAW JY, CORNFIELD LJ, BALFOUR C, MASH E: Selective inactivation of rat liver cytochromes P450 by 21-chlorinated steroids. Drug Metab. Disp. (1989) 17:26–31.
   PubMed Web of Science ®Google Scholar
• CORREIA MA, YAO K, WRIGHTON SA, WAXMAN DJ, RET-TIE AE: Differential apoprotein loss of rat liver cyto-chromes P450 after their inactivation by 3:5-dicarbe-thoxy-2,6-dimethy1-4-ethy1-1,4-dihydropyridine: a case for distinct proteolytic mechanism. Arch. Biochem. Bio-phy. (1992) 294:493–503.
   PubMed Web of Science ®Google Scholar
• MANOME Y, WEN PY, CHEN L et al: Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cyto-chrome P-450 2B1 gene together with cyclophos-phamide. Gene Ther. (1996) 3:513–520.
   PubMed Web of Science ®Google Scholar
• CHEN L, WAXMAN DJ, CHEN D, KUFE DC: Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P-450 gene. Cancer Res. (1996) 56:1331–1340.
   PubMed Web of Science ®Google Scholar
• SHERWOOD RF, MELTON RG, ALWAN SM, HUGHES P: Purification and properties of carboxypeptidase G2 Pseudonomas spp. strain RS-16. Eur. j Biochem. (1985) 148:447–453.
   PubMed Web of Science ®Google Scholar
• SPRINGER CJ, ANTONIW P, BAGSHAWE KD eta].: Novelprodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase Gy. J. Med. Chem. (1990) 33:677–681.
   Google Scholar
• KHAN AC, ROSS WCJ: Tumour growth inhibitory Ili-trophenylaziridines and related compounds: structure activity relationships. Chem. Biol. Interact (1967) 1:27–47.
   Google Scholar
• KNOX RJ, BOLAND MP, FRIEDLOS F eta].: The nitroreduc- tase enzyme in Walker cells that activates 5-(aziricin-1-y0-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-y0-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Bio-chem. Pharmacol (1988) 44:2297–2301.
   Google Scholar
• KNOX RJ, FRIEDLOS F, SHERWOOD RF eta].: The bioacti- vation of 5-(aziridin-1-y1)-2,4-dinitrobenzamide (CB 1954). II. A comparison of an Escherichia coli nitrore-ductas e and Walker DT-di aphor ase . Biochem. Pharmacol (1992) 44:2297–2301.
   Google Scholar
• BOLAND MP, KNOX RJ, ROBERTS JJ: The differences in kinetics of rat and human DT-diaphorase result in a differential sensitivity of cells lines to CB 1954 [5-(az-iridin-1-y1)-2,4-dinitrobenzamide. Biochem. Pharmacol (1991) 41:867–875.
   PubMed Web of Science ®Google Scholar
• FREEMAN SM, ABBOUD CN, WHARTENBY KA eta].: The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. (1993) 53:5274–5283.
   Google Scholar
• TRINH QT, AUSTIN EA, MURRAY DM, KNICK VC, HUBER BE: Enzyme/prodrug gene therapy: comparison of cy-tosine deaminase/5-fluoro cytosine versus thymidine kinase/gancyclovir enzyme/prodrug system in a hu-man colorectal carcinoma cell line. Cancer Res. (1995) 55:4808–4812.
   PubMed Web of Science ®Google Scholar
• FICK J, BARKER FG, DAZIN P eta].: The extent of hetero-cellular communication mediated gap junctions is pre-dictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci USA (1995) 92:11071–11075.
   Google Scholar
• GOLDBERG G, BERTRAM JS: Correspondence re: Z Ram et al, in situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res., 53:83-88:1993. Cancer Res. (1994) 54:3947–3948.
   Google Scholar
• DAGHER SF, CONRAD SE, WERNER EA, PATTERSON RJ: Phenotypic conversion of TK-deficient cells following electroporation of functional TK enzyme. Exp. Cell Res. (1992) 198:36–42.
   PubMed Web of Science ®Google Scholar
• HAMEL W, MAGNELLI L, CHIARUGI VP, ISRAEL MA: Herpessimplex virus thymidine kinase/gancyclovir-mediated apoptotic death of bystander cells. Cancer Res. (1996) 56:2697–2702.
   PubMed Web of Science ®Google Scholar
• RAMESH R, MARRO GI AJ, MUNSHI A eta].: In vivo analys is of the 'bystander effect': a cytokine cascade. Exp. Hema-tol. (1996) 24:829–838.
   Google Scholar
• GAGANDEP S, BREW R, GREEN B eta].: Prodrug-activated gene therapy: involvement of an immunological com-ponent in the 'bystander effect'. Gene Ther. (1996) 3:83–
   Google Scholar
• OLDFIELD EH, RAM Z, CULVER KW, BLAESE RM, DEVROOM HL: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with thymid-ine kinase gene and intravenous gancyclovir. Human Gene Ther. (1993) 4:39.
   PubMed Web of Science ®Google Scholar